Vargatef 150mg Soft Capsules
- Name:
Vargatef 150mg Soft Capsules
- Company:
Boehringer Ingelheim Limited
- Active Ingredients:
- Legal Category:
Product subject to medical prescription which may not be renewed (A)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 21/01/20
(Click to Download)Click on this link to Download PDF directly
Boehringer Ingelheim Limited
Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 21 January 2020 PIL
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 20 January 2020 SmPC
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
- Section 4.8: Addition of new ADRs ‘Headache’ (frequency common) & ‘Alopecia’ (frequency very common)
- Section 10: Date of revision has been updated to 12/2019
Updated on 11 September 2019 PIL
Reasons for updating
- Change to section 2 - what you need to know - contraindications
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 2 - driving and using machines
- Change to section 3 - how to take/use
- Change to section 4 - possible side effects
- Change to section 6 - what the product contains
- Change to section 6 - date of revision
- Removal of Black Inverted Triangle
Updated on 10 September 2019 SmPC
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 3 - Pharmaceutical form
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 6.1 - List of excipients
- Change to section 6.5 - Nature and contents of container
- Change to section 8 - Marketing authorisation number(s)
- Change to section 9 - Date of first authorisation/renewal of the authorisation
- Change to section 10 - Date of revision of the text
- Removal of Black Inverted Triangle
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
· Removal of black triangle
· Sections 2, 3, 4.2, 4.3, 4.5, 4.6, 4.8, 5.1, 5.2, 6.1, 6.5, 8 & 9: minor administrative/editorial changes, including addition of the latest renewal approval date
· Section 4.4 & 4.8: To add a warning and an ADR regarding ‘aneurysms and artery dissections’ (PRAC recommendation to update the product information of respective EU Marketing Authorisation Holders for the class of VEGF inhibitors)
· Section 10: Date of revision has been updated to 08/2019
Updated on 16 August 2019 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
- Change to section 4 - how to report a side effect
- Change to section 6 - date of revision
Updated on 16 August 2019 SmPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 9 August 2018 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 9 August 2018 SmPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
- Section 4.4: Update regarding gastrointestinal perforations and Renal function.
- Section 4.8: Addition of ‘Myocardial Infarction´ & ‘Renal Failure’ as ADRs.
- Section 4.8: Addition of ‘Pruritus´ as an ADR.
- Section 10: Date of revision of the text has been aligned to 07/2018
Updated on 11 June 2018 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 6 - date of revision
- Change to other sources of information section
Updated on 8 June 2018 SmPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 24 November 2017 PIL
Reasons for updating
- New PIL for new product
Updated on 24 November 2017 PIL
Reasons for updating
- Change to other sources of information section
- Improved presentation of PIL
Updated on 18 October 2017 PIL
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 17 October 2017 SmPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
· Section 4.4: Updated to amend the current warning on hepatic function to include drug liver induced injury associated with nintedanib administration and to include low body weight, Asian origin, female sex and age as factors of increased risk of liver enzymes elevations.
· Section 4.8: Updated to add ‘weight decreased’ and ‘drug-induced liver injury’ (DILI) as new adverse drug reactions.
· Section 5.2: Update to amend the current information related to the mean exposure to nintedanib in the ‘Race’ sub-section.
· Section 10: Date of revision has also been updated to 09/2017.
Updated on 17 October 2017 SmPC
Reasons for updating
- New SmPC for new product
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 31 August 2017 SmPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
· Sections 4.4: Following wording update in the ‘Gastrointestinal disorders’ subsection;
Ø Information regarding post-marketing serious cases of diarrhoea has been added.
Ø Information regarding interruption, dose reduction and discontinuation of Vargatef therapy may be required in an event of dehydration, has been added.
· Sections 4.4: Following wording update in the ‘Haemorrhage’ subsection;
Ø Information regarding post-marketing serious and non-serious events of bleeding has been added.
· Sections 4.8: Information in the ‘Bleeding’ subsection has been updated in line with the wording in section 4.4. A cross-reference to section 4.4 has also been added for the side effect ‘Bleeding’.
Section 10: Date of revision of the text has also been aligned to 08/2017 with the date of Commission decision, which was 14/08/2017.
Updated on 31 August 2017 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - how to report a side effect
- Change to section 6 - date of revision
Updated on 6 April 2017 PIL
Reasons for updating
- Improved presentation of PIL
Updated on 9 March 2017 SmPC
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 10, date of revision of the text has been aligned with date of commission decision (23Feb17).
Updated on 7 March 2017 PIL
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 13 January 2017 PIL
Reasons for updating
- Improved presentation of PIL
Updated on 21 December 2016 PIL
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 6 - what the product looks like and pack contents
- Change to section 6 - date of revision
Updated on 20 December 2016 SmPC
Reasons for updating
- Change to section 3 - Pharmaceutical form
- Change to section 4.8 - Undesirable effects
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
The following sections have been updated:
- Section 3 3 pharmaceutical form changed to include (capsule)
- Section 4.8 Undesirable effects updated in include Thrombocytopenia plus typographical changes including Malta website address aligned with Appendix V (‘Website:’ added)
- Section 10 Date of revision of the text updated to reflect PO date: 10Nov16
Updated on 19 October 2016 SmPC
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 5.3 - Preclinical safety data
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
A typographical correction has been made in section 5.3 (Preclinical safety data).
Section 10 the date of revision has been amended.
Updated on 14 September 2016 PIL
Reasons for updating
- Change to side-effects
- Change to date of revision
Updated on 30 August 2016 SmPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Sections 4.4 and 4.8: Additional common side effect added under the class of Hepatobiliary disorders – ‘Gamma-glutamyl transferase increased’
Section 4.8: Malta Adverse Event reporting address updated to align with QRD template, Appendix V
Section 10: revision date has been revised in line with the commission decision date of the variation (18 August 2016)
Updated on 29 February 2016 SmPC
Reasons for updating
- Change to section 5.3 - Preclinical safety data
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 10 - Date of revision of the text
- Change to joint SPC covering all presentations
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Sections 4.2, 4.4 and 5.2 - changes have been introduced regarding hepatic function and impairment.
Section 5.3 change from
In rats, embryofoetal lethality and teratogenic effects were observed at exposure levels below human exposure, at the maximum recommended human dose (MRHD) of 250 mg b.i.d.. Effects on the development of the axial skeleton and on the development of the great arteries were also noted at subtherapeutic exposure levels.
to
In rats, embryofoetal lethality and teratogenic effects were observed at exposure levels below human exposure, at the maximum recommended human dose (MRHD) of 200 mg b.i.d.. Effects on the development of the axial skeleton and on the development of the great arteries were also noted at subtherapeutic exposure levels.
Section 10 - date of revision amended.
Updated on 29 April 2015 PIL
Reasons for updating
- Improved electronic presentation
Updated on 24 March 2015 PIL
Reasons for updating
- Change to storage instructions
- Change to further information section
- Change to date of revision
Updated on 18 March 2015 SmPC
Reasons for updating
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 9 - Date of renewal of authorisation
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 5.1 Pharmacodynamic Properties
The ATC code of L01XE31 has been added to this section. The previous text of not yet assigned has been deleted.
Section 9 Date of First Authorisation/Renewal of the Authorisation
The text Date of first authorisation: has been added to this section.
Section 10 Date of Revision of the Text
The date of March 2015 has been added to this section.
Updated on 3 February 2015 PIL
Reasons for updating
- New PIL for new product
Updated on 23 January 2015 SmPC
Reasons for updating
- New SPC for new product
Legal category: Product subject to medical prescription which may not be renewed (A)